Christel Herold-Mende

List of Publications by Year
in descending order

		66234		27345	
150 papers	12,796 citations	42 h-index	106 g-index

| 154 all docs | 154 docs citations | 154 times ranked | 16522 citing authors |

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
2	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	3.9	1,020
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
4	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
5	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
6	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	5.1	582
7	Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nature Communications, 2019, 10, 1787.	5.8	379
8	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	15.2	359
9	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Journal of Clinical Investigation, 2017, 127, 1425-1437.	3.9	334
10	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	3.9	298
11	Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β. Clinical Cancer Research, 2011, 17, 4296-4308.	3.2	290
12	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	3.0	283
13	Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells. Clinical Cancer Research, 2010, 16, 2715-2728.	3.2	279
14	Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor TCF21 via GADD45A. Molecular Cell, 2014, 55, 604-614.	4.5	242
15	Radiogenomics of Glioblastoma: Machine Learning–based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. Radiology, 2016, 281, 907-918.	3.6	236
16	When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma. International Journal of Molecular Sciences, 2018, 19, 436.	1.8	231
17	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathologica, 2016, 131, 903-910.	3.9	203
18	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	3.9	195

#	Article	IF	Citations
19	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	0.6	184
20	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell, 2019, 35, 692-704.e12.	7.7	172
21	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	3.9	146
22	Different angiogenic phenotypes in primary and secondary glioblastomas. International Journal of Cancer, 2006, 118, 2182-2189.	2.3	126
23	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathologica, 2020, 140, 409-413.	3.9	116
24	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. Cell Metabolism, 2019, 30, 274-289.e5.	7.2	115
25	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	3.9	109
26	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	3.9	104
27	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	0.6	102
28	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	0.6	100
29	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	0.8	93
30	EXPRESSION OF CD44 SPLICE VARIANTS IN SQUAMOUS EPITHELIA AND SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK. , 1996, 179, 66-73.		79
31	Mechanistic Studies on a Novel, Highly Potent Gold-Phosphole Inhibitor of Human Glutathione Reductase. Journal of Biological Chemistry, 2005, 280, 20628-20637.	1.6	78
32	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	3.9	74
33	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica, 2019, 138, 295-308.	3.9	74
34	Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. , 1999, 80, 194-198.		70
35	Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget, 2016, 7, 31955-31971.	0.8	69
36	Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. JCI Insight, 2019, 4, .	2.3	63

#	Article	IF	Citations
37	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
38	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504.	3.9	57
39	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	3.9	56
40	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	3.2	55
41	Aberrant self‐renewal and quiescence contribute to the aggressiveness of glioblastoma. Journal of Pathology, 2014, 234, 23-33.	2.1	53
42	The genomic and transcriptional landscape of primary central nervous system lymphoma. Nature Communications, 2022, 13, 2558.	5.8	52
43	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. BMC Cancer, 2016, 16, 81.	1.1	51
44	Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas. Biomarkers, 2011, 16, 136-143.	0.9	46
45	Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 112-119.	0.4	46
46	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
47	IDH1 mutations induce organelle defects via dysregulated phospholipids. Nature Communications, 2021, 12, 614.	5.8	44
48	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. PLoS ONE, 2012, 7, e41298.	1.1	43
49	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathologica, 2019, 138, 827-835.	3.9	42
50	MetaboDiff: an R package for differential metabolomic analysis. Bioinformatics, 2018, 34, 3417-3418.	1.8	41
51	Expression and regulation of AC133 and CD133 in glioblastoma. Glia, 2011, 59, 1974-1986.	2.5	40
52	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro-Oncology, 2017, 19, 1607-1617.	0.6	39
53	Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Science, 2011, 102, 387-392.	1.7	38
54	Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. International Journal of Cancer, 2014, 135, 2727-2734.	2.3	38

#	Article	IF	Citations
55	Comparison of the RGD Motif–Containing α$_v$β$_6$ Integrin–Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. Journal of Nuclear Medicine, 2018, 59, 1679-1685.	2.8	38
56	Antiglioma activity of 2,2′:6′,2″-terpyridineplatinum(II) complexes in a rat model—Effects on cellular redox metabolism. Free Radical Biology and Medicine, 2006, 40, 763-778.	1.3	37
57	Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display. Clinical Cancer Research, 2017, 23, 4170-4180.	3.2	37
58	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568.	0.8	36
59	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	0.6	32
60	Identification of KIF11 As a Novel Target in Meningioma. Cancers, 2019, 11, 545.	1.7	31
61	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. Neuro-Oncology, 2020, 22, 480-492.	0.6	31
62	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	3.9	31
63	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. International Journal of Molecular Sciences, 2018, 19, 2903.	1.8	30
64	Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. Radiology and Oncology, 2013, 47, 330-337.	0.6	29
65	Expression of SGLT-1 in preoplastic and neoplastic lesions of the head and neck. Oral Oncology, 2004, 40, 28-35.	0.8	28
66	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	2.4	28
67	Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. Clinical Neurology and Neurosurgery, 2016, 142, 72-80.	0.6	26
68	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. Acta Neuropathologica, 2017, 134, 155-158.	3.9	26
69	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. Journal of Neuro-Oncology, 2016, 129, 319-328.	1.4	25
70	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. Clinical Cancer Research, 2018, 24, 2951-2962.	3.2	25
71	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. Cancers, 2019, 11, 122.	1.7	25
72	Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. Cancer Immunology, Immunotherapy, 2019, 68, 2005-2014.	2.0	24

#	Article	IF	Citations
73	AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. Nature Communications, 2020, 11, 6366.	5.8	24
74	Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties. Neuro-Oncology, 2021, 23, 1898-1910.	0.6	24
75	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. Acta Neuropathologica, 2017, 134, 297-316.	3.9	23
76	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. Cancers, 2019, 11, 2028.	1.7	23
77	Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e108908.	1.1	22
78	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro-Oncology, 2021, 23, 226-239.	0.6	22
79	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. Neuro-Oncology, 2022, 24, 39-51.	0.6	22
80	PET/CT Imaging of NSCLC with a $\alpha v\beta 6$ Integrin-Targeting Peptide. Molecular Imaging and Biology, 2019, 21, 973-983.	1.3	21
81	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 1931.	1.8	20
82	Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. Viruses, 2016, 8, 138.	1.5	19
83	Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. Cancer Immunology, Immunotherapy, 2017, 66, 593-603.	2.0	19
84	DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer. Clinical Epigenetics, 2019, 11, 67.	1.8	19
85	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. Acta Neuropathologica, 2022, 143, 609-612.	3.9	19
86	Antitumor Immunization of Head and Neck Squamous Cell Carcinoma Patients with a Virus-Modified Autologous Tumor Cell Vaccine. , 2004, 62, 173-183.		18
87	Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. International Journal of Cancer, 2012, 131, 1963-1968.	2.3	18
88	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	2.3	18
89	Volumetric assessment of glioblastoma and its predictive value for survival. Acta Neurochirurgica, 2019, 161, 1723-1732.	0.9	18
90	Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. Cancers, 2019, 11, 284.	1.7	18

#	Article	IF	Citations
91	Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica, 2022, 143, 263-281.	3.9	18
92	Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. Neurosurgery, 2019, 85, E722-E729.	0.6	17
93	Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents. Cells, 2020, 9, 1389.	1.8	17
94	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Letters, 2021, 506, 1-10.	3.2	17
95	Identification of Ligands and Translation to Clinical Applications. Journal of Nuclear Medicine, 2017, 58, 27S-33S.	2.8	16
96	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. Cancers, 2019, 11, 1072.	1.7	16
97	Clinical and immunological correlates of long term survival in glioblastoma. Wspolczesna Onkologia, 2018, 2018, 81-85.	0.7	15
98	A PRDX1â€p38Î± heterodimer amplifies METâ€driven invasion of <i>IDH</i>â€wildtype and <i>IDH</i>â€mutant gliomas. International Journal of Cancer, 2018, 143, 1176-1187.	2.3	14
99	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. Cancer & Metabolism, 2020, 8, 23.	2.4	14
100	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia, 2015, 63, 1850-1859.	2.5	13
101	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	3.9	12
102	Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway. Cancer Letters, 2018, 428, 69-76.	3.2	12
103	Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide. Cancers, 2021, 13, 3577.	1.7	12
104	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. Acta Neuropathologica Communications, 2022, 10, 5.	2.4	12
105	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. Cancers, 2018, 10, 486.	1.7	11
106	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. Acta Neuropathologica, 2018, 136, 975-978.	3.9	11
107	Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. International Journal of Radiation Oncology Biology Physics, 2022, 112, 499-513.	0.4	10
108	Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1065-1074.	0.9	10

#	Article	IF	Citations
109	Helping EGFR inhibition to block cancer. Nature Neuroscience, 2017, 20, 1035-1037.	7.1	9
110	Impact of post-surgical freezing delay on brain tumor metabolomics. Metabolomics, 2019, 15, 78.	1.4	9
111	The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. Neurosurgical Review, 2021, 44, 2707-2715.	1.2	9
112	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making â€" A Selected Case Series. Klinische Padiatrie, 2018, 230, 305-313.	0.2	8
113	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. International Journal of Cancer, 2019, 145, 3436-3444.	2.3	8
114	ï»¿Preclinical evaluation of peptide-based radiotracers for integrin Î±vÎ²6-positive pancreatic carcinoma. Nuklearmedizin - NuclearMedicine, 2019, 58, 309-318.	0.3	8
115	Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. International Journal of Molecular Sciences, 2020, 21, 7801.	1.8	8
116	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers, 2020, 12, 3270.	1.7	8
117	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neuro-Oncology Advances, 2020, 2, vdz060.	0.4	8
118	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. PLoS ONE, 2018, 13, e0193242.	1.1	8
119	Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biology and Therapy, 2014, 15, 436-442.	1.5	7
120	Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers, 2021, 13, 5898.	1.7	7
121	Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. Head and Neck, 2018, 40, 2685-2694.	0.9	6
122	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. Acta Neuropathologica, 2019, 138, 275-293.	3.9	6
123	Gold(<scp>i</scp>) complexes based on six-membered phosphorus heterocycles as bio-active molecules against brain cancer. Chemical Communications, 2020, 56, 14593-14596.	2.2	6
124	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. Cancers, 2020, 12, 2583.	1.7	6
125	A New Pentafluorothio-Substituted Curcuminoid with Superior Antitumor Activity. Biomolecules, 2021, 11, 947.	1.8	6
126	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. Cancers, 2022, 14, 339.	1.7	6

#	Article	IF	Citations
127	Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. Anticancer Research, 2016, 36, 1489-96.	0.5	6
128	Diagnostic potential of extracellular vesicles in meningioma patients. Neuro-Oncology, 2022, 24, 2078-2090.	0.6	6
129	Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines. Cancers, 2021, 13, 1327.	1.7	5
130	Luminescent Pyrroleâ€based Phosphaphenalene Gold Complexes: A Versatile Anticancer Tool with a Wide Applicability. Chemistry - A European Journal, 2022, , .	1.7	5
131	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 2960.	1.8	4
132	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÂ²MÂ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	0.8	4
133	VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061.	0.8	4
134	Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells. Current Pharmaceutical Design, 2014, 20, 66-72.	0.9	4
135	HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. Neuro-Oncology, 2022, , .	0.6	4
136	Luminescent Pyrroleâ€Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability. Chemistry - A European Journal, 2022, 28, .	1.7	4
137	Non-invasive glioblastoma immunoprofiling by printed peptide arrays. OncoImmunology, 2016, 5, e1069941.	2.1	3
138	An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment. Cancers, 2021, 13, 568.	1.7	3
139	Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.. Journal of Clinical Oncology, 2019, 37, 2012-2012.	0.8	3
140	Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients. Cancers, 2021, 13, 1601.	1.7	2
141	Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study. Cancers, 2021, 13, 3435.	1.7	2
142	Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy. Cancers, 2022, 14, 684.	1.7	2
143	PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme.. Journal of Clinical Oncology, 2021, 39, 2041-2041.	0.8	1
144	DDIS-21. KIF11 INHIBITORS FILANESIB AND ISPINESIB AS NOVEL AGENTS FOR MENINGIOMA THERAPY. Neuro-Oncology, 2018, 20, vi73-vi73.	0.6	0

#	Article	IF	Citations
145	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i130-i130.	0.6	0
146	SURG-19. IMPACT OF INTRAOPERATIVE MAGNETIC RESONANCE IMAGING ON THE EXTENT OF RESECTION AND FUNCTIONAL OUTCOME IN AWAKE SURGERY FOR ELOQUENT GLIOMAS â€" A SINGLE CENTER RETROSPECTIVE STUDY. Neuro-Oncology, 2018, 20, vi254-vi254.	0.6	0
147	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
148	Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. Anticancer Research, 2015, 35, 2681-90.	0.5	0
149	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and*in vivo* validation. Neuro-Oncology, 2022, 24, i168-i169.	0.6	0
150	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	0.6	0